MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Country |
 USA |
IPO year |
2016 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
22 M |
Market Cap[1] |
$ 2.64 M |
EBITDA (LTM) |
$ -43.9 M |
P/E (LTM) |
- |
P/S (LTM) |
0.16 |
EPS (LTM) |
-1.94 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Compugen Ltd.
CGEN
|
$ 2.86 | 3.62 % | $ 267 M | Nasdaq Global Market,SPB |  Israel |
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market |  Canada |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.8 | -3.59 % | $ 36.6 M | Nasdaq Capital Market | Israel |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Exelixis
EXEL
|
$ 46.21 | -5.11 % | $ 12.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Fortress Biotech
FBIO
|
$ 2.4 | -5.88 % | $ 67 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 93.02 | -2.35 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
|
Forte Biosciences
FBRX
|
$ 26.17 | -1.32 % | $ 339 M | Nasdaq Capital Market | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 22.56 | 5.03 % | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Esperion Therapeutics
ESPR
|
$ 3.14 | -0.32 % | $ 653 M | Nasdaq Global Market,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.54 | 3.51 % | $ 5.83 M | NYSE American | Israel |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Genprex
GNPX
|
$ 0.87 | -2.84 % | $ 811 K | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 20.66 | -14.52 % | $ 2.63 B | Nasdaq Global Select Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Genmab A/S
GMAB
|
$ 27.06 | -2.98 % | $ 16.7 B | Nasdaq Global Select Market |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 52.42 | -4.83 % | $ 4.71 B | Nasdaq Global Market,SPB |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.61 | -5.29 % | $ 428 M | Nasdaq Global Select Market | Britain |
 |
Heron Therapeutics
HRTX
|
$ 1.24 | -5.34 % | $ 207 M | Nasdaq Global Select Market,SPB | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.